美国国立卫生研究院的Rafael de Cabo、Michel Bernier等研究人员合作发现，双硫仑治疗可使肥胖小鼠的体重正常化。相关论文于2020年5月14日在线发表在《细胞—代谢》上。
Title: Disulfiram Treatment Normalizes Body Weight in Obese Mice
Author: Michel Bernier, Sarah J. Mitchell, Devin Wahl, Antonio Diaz, Abhishek Singh, Wonhyo Seo, Mingy Wang, Ahmed Ali, Tamzin Kaiser, Nathan L. Price, Miguel A. Aon, Eun-Young Kim, Michael A. Petr, Huan Cai, Alessa Warren, Clara Di Germanio, Andrea Di Francesco, Ken Fishbein, Vince Guiterrez, Dylan Harney, Yen Chin Koay, John Mach, Ignacio Navas Enamorado, Tamara Pulpitel, Yushi Wang, Jing Zhang, Li Zhang, Richard G. Spencer, Kevin G. Becker, Josephine M. Egan, Edward G. Lakatta, John O’Sullivan, Mark Larance, David G. LeCouteur, Victoria C. Cogger, Bin Gao, Carlos Fernandez-Hernando, Ana Maria Cuervo, Rafael de Cabo
Abstract: Obesity is a top public health concern, and a molecule that safely treats obesityis urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatmentfor chronic alcohol addiction, exhibits anti-inflammatory properties and helps protectagainst certain types of cancer. Here, we show that in mice disulfiram treatment preventedbody weight gain and abrogated the adverse impact of an obesogenic diet on insulinresponsiveness while mitigating liver steatosis and pancreatic islet hypertrophy.Additionally, disulfiram treatment reversed established diet-induced obesity and metabolicdysfunctions in middle-aged mice. Reductions in feeding efficiency and increases inenergy expenditure were associated with body weight regulation in response to long-termdisulfiram treatment. Loss of fat tissue and an increase in liver fenestrations werealso observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents,repurposing disulfiram in the clinic could represent a new strategy to treat obesityand its metabolic comorbidities.